Anti-VPS15 antibody [EPR5302(2)]

4 product images

• 

  Western blot - Anti-VPS15 antibody [EPR5302(2)] (ab128903)

  This antibody detects high background.
  

  Blocking/Diluting buffer: 5% NFDM/TBST

  All lanes: Western blot - Anti-VPS15 antibody [EPR5302(2)] (ab128903) at 1/1000 dilution

  All lanes: Raji (Human Burkitt's lymphoma B lymphocyte) whole cell lysates at 15 µg

  Secondary

  All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution

  Predicted band size: 153 kDa

  Observed band size: 150 kDa

• 

  Western blot - Anti-VPS15 antibody [EPR5302(2)] (ab128903)

  Blocking/Diluting buffer: 5% NFDM/TBST
  

  This antibody detects high background.

  All lanes: Western blot - Anti-VPS15 antibody [EPR5302(2)] (ab128903) at 1/500 dilution

  Lane 1: Mouse E14.5 brain lysates at 20 µg

  Lane 2: Rat E14 brain lysates at 20 µg

  Lane 3: Rat P0 brain lysates at 20 µg

  Lane 4: C6 (Rat glial tumor glial cell) whole cell lysates at 20 µg

  Lane 5: Neuro-2a (Mouse neuroblastoma neuroblast) whole cell lysates at 20 µg

  Secondary

  All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution

  Predicted band size: 153 kDa

  Observed band size: 150 kDa

• 

  OI-RD Scanning - Anti-VPS15 antibody [EPR5302(2)] (ab128903)

  We have systematically measured KD (the equilibrium dissociation constant between the antibody and its antigen), of more than 840 recombinant antibodies to assess not only their individual KD values but also to see the average affinity of antibody.
  Based on the comparison with published literature values for mouse monoclonal antibodies, Recombinant antibodies appear to be on average 1-2 order of magnitude higher affinity.

• 

  Image collected and cropped by CiteAb under a CC-BY license from the publication

  Western blot - Anti-VPS15 antibody [EPR5302(2)] (ab128903)

  VPS15 western blot using anti-VPS15 antibody [EPR5302(2)] ab128903. Publication image and figure legend from Wang, M., Tang, C., et al., 2021, Mol Psychiatry, PubMed 30531936.

  
  

  ab128903 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab128903 please see the product overview.

  WDR81 suppresses PI3K-III activity in aNPCs. a Analysis of PI3K activity in Wdr81f/f aNPCs infected with lenti-dCreGFP or lenti-CreGFP (dCre vs. Cre, t test, p = 0.049; dCre, n = 3 independent experiments, Cre, n = 3 independent experiments). b 2xFYVE-mCherry-positive endosomes in Wdr81f/f aNPCs infected with lenti-CreGFP or lenti-dCreGFP. Scale bars, 5 µm. c Analysis of the size of 2xFYVE-mCherry endosomes in Wdr81f/f aNPCs infected with lenti-dCreGFP or lenti-CreGFP (dCre vs. Cre, t test, p < 0.0001; n = 20 cells from three independent experiments). d PtdIns3P ELISA analysis of Wdr81f/f aNPCs infected with lenti-dCreGFP or lenti-dCreGFP (dCre vs. Cre, t test, p = 0.036; dCre, n = 3 independent experiments, Cre, n = 3 independent experiments). e–g Co-IP of FLAG-WDR81 with HA-Beclin1, V5-VPS15, and GFP−VPS34. h and i Co-IP of VPS15 with VPS34 in WT and WDR81 KO cells (h) and quantification of the co-IP efficacy normalized to input (i, IP: VPS34, WT vs. KO, t test, p = 0.013; IP: VPS15, WT vs. KO, t test, p = 0.044; WT, n = 3 independent experiments, KO, n = 3 independent experiments). j and k Co-IP of Beclin1 with VPS34 in WT and WDR81 KO cells (j) and quantification of the co-IP efficacy normalized to input (k, IP: VPS34, WT vs. KO, t test, p = 0.514; IP: Beclin1, WT vs. KO, t test, p = 0.961, WT, n = 3 independent experiments, KO, n = 3 independent experiments). l Experimental scheme for assessing the proliferation and differentiation of aNPCs in the DG of adult hippocampus after TAM injection and 3-MA treatment. m Sample images of the DG stained with BrdU, Sox2, and GFAP at 2 h after BrdU injection. Scale bars, 20 µm. n Quantification of BrdU+GFAP−Sox2+ cells in the DG of Wdr81 cKO mice and WT mice treated with or without 3-MA at 2 h after BrdU injection (WT vs. WT + 3-MA, t test, p = 0.043; and cKO vs. cKO + 3-MA, t test, p = 0.014; WT, n = 5 mice, WT + 3-MA, n = 4 mice, cKO, n = 5 mice, cKO + 3-MA, n = 5 mice). o Sample images of the DG stained with BrdU and NeuN at 4 weeks after BrdU injection. Scale bars, 20 µm. p Quantification of BrdU+NeuN+ neurons in the DG of Wdr81 cKO mice and WT mice treated with 3-MA at 4 weeks after BrdU labeling (WT vs. WT + 3-MA, t test, p = 0.025; and cKO vs. cKO + 3-MA, t test, p = 0.012; WT, n = 5 mice, WT + 3-MA, n = 4 mice, cKO, n = 5 mice, cKO + 3-MA, n = 5 mice). Data are presented as mean ± SEM; *p < 0.05, ***p < 0.001